ClinicalTrials.gg
Enrolling by invitationNCT07298993DEPRESCRIBEUpdated Oct 16, 2026

Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)

A Phase 4 interventional study of Placebo (matching) and Beta-blockers in Heart Failure, HFpEF and HFpEF - Heart Failure With Preserved Ejection Fraction, sponsored by Weill Medical College of Cornell University. Enrolling by invitation at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Weill Medical College of Cornell University · Phase 4, Interventional, and Treatment

How we know

Updated Oct 16, 2026Eligibility revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies testing Beta blockers in Heart Failure — 9 open to participants now, 9 under way, none of them phase 3. A drug class: Beta blockers · Heart Failure.

Planned enrollment
11th of 55
240 · median 63
Started
2026
with 1 other
Phase 4
27 of 56
6 open now
Registered
56th of 56
by date
Lead sponsor
6 of 56
Weill Medical College of Cornell University

Among the 56 studies testing Beta blockers in Heart Failure, this one is the 11th largest by planned enrollment of the 55 interventional ones that give a count, is one of 2 that started in 2026, is one of 27 in phase 4, and was the 56th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

9 of the 56 studies testing Beta blockers in Heart Failure are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About Beta blockers

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing Beta blockers in Heart Failure, or all of them as a file.
02

Study summary

The goal of this study is to learn whether stopping beta-blockers can help older adults with heart failure with preserved ejection fraction (HFpEF) feel better and function better. This study will test whether "deprescribing" or stopping these medications in a careful, guided way can improve symptoms and quality of life.

Participants will be randomly assigned to one of two groups:

Deprescribing group: Beta-blockers are gradually reduced using capsules that contain decreasing doses.

Usual care group: Beta-blockers are continued at the usual dose in look-alike capsules.

All participants will:

  • Take study medicine for about 4 months
  • Have their blood pressure and heart rate monitored
  • Complete regular phone calls and questionnaires about how they are feeling

This study does not involve any experimental medication. Participants active involvement in the study will last approximately 4 months. During these 4 months they will have 8 scheduled telephone visits.

03

Conditions studied

  • Heart Failure
  • HFpEF
  • HFpEF - Heart Failure With Preserved Ejection Fraction

Browse trials for

Keywords

  • Heart Failure
  • Heart Failure with Preserved Ejection Fraction
  • HFPEF
  • Deprescribing
04

Who can participate

The criteria were revised on the registry on Oct 16, 2026. See what changed

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ambulatory adults age ≥60 years with HFpEF (EF ≥50% based on most recent transthoracic echocardiogram)
  2. Evidence of HF, defined by at least one of the following:

    • Hospitalized with HF in the past 24 months (defined by diagnostic codes in any position)
    • BNP >100 pg/mL in the past 24 months
  3. Taking any of the following ß-blockers: atenolol, bisoprolol, carvedilol, metoprolol succinate, or metoprolol tartrate (i.e., pharmacy prescription data)
  4. Kaiser Permanente Northern California Membership

Exclusion criteria

Exclusion Criteria:

  1. Alternative etiologies of HFpEF syndrome
  2. Compelling guideline indication for ß-blocker:

    • Prior EF \<50% (i.e., based on the structured data field on transthoracic echocardiogram)
    • Current anginal symptoms (i.e., based on the Rose Angina single-question screener for angina)
    • MI (i.e., diagnostic codes) and/or coronary revascularization (i.e., procedure codes) within 3 years
    • Hospitalization for a primary discharge diagnosis of atrial fibrillation or atrial flutter with a rapid ventricular response in the prior 12 months (i.e., not for an elective procedure such as a cardioversion or an ablation)
    • Other documented reason in the opinion of the treating provider and/or enrolling clinician-investigator
  3. Hospitalization for a primary discharge diagnosis of HF within the past 30 days.
  4. Estimated \<6 months (i.e., diagnostic codes)
  5. Diagnosed dementia (i.e., diagnostic codes)
  6. Unable to provide
  7. Loss of Kaiser Permanente Northern California Membership
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Placebo comparator
    Deprescribe

    Participants will have their beta-blocker replaced with pills that have decreasing amounts of beta-blocker until they are completely off their medicine and taking placebo pills.

    Drug: Placebo (matching)

  • Active comparator
    Continuation

    Participants will continue their beta-blocker at their usual dose in capsules that look identical to those used for the deprescribe arm.

    Drug: Beta-blockers

Interventions

  • DrugPlacebo (matching)

    Beta-blocker dosage will be reduced over the course of 4 weeks until the participant is completely off of beta-blocker and transitioned to matching placebo capsules.

    Also known as: Deprescribing

  • Participants will continue their pre-enrollment beta-blocker at the same dose. The beta-blocker agent may include atenolol, bisoprolol, carvedilol, metoprolol succinate, or metoprolol tartrate. Medication will be provided in matching capsules to maintain blinding.

    Also known as: Atenolol, Bisoprolol, Carvedilol, Metoprolol succinate, Metoprolol tartrate

06

What researchers measure

Primary outcomes

  1. The Hierarchical Composite Endpoint

    The primary outcome is net benefit, assessed using a hierarchical composite of four patient-centered outcomes: (1) time to death from any cause, (2) time to all-cause hospitalization, (3) ≥ 5-point difference of KCCQ-12 OSS change from baseline, and (4) ≥ 3-point difference in PROMIS Depression T-score change from baseline

    Time frame: From baseline (randomization) to 120 days after study drug initiation

Secondary outcomes

  1. The change from baseline in patient-reported physical health, as measured by the KCCQ-12

    The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) is a heart failure-specific health status survey. The 12-item questionnaire asks participants to rate their agreement with a series of statements using a six-point Likert scale, ranging from "completely disagree" (0) to "completely agree" (5). Item responses are summed to generate a total score ranging from 0 to 100, with higher scores indicating better health status.

    Time frame: From baseline (randomization) to 120 days after study drug initiation

  2. The change in patient-reported mental health, as measured by the PROMIS Depression scale

    The PROMIS Depression scale is a validated 4-item patient-reported measure developed by the NIH, with high reliability and responsiveness in older adults. The 4-item questionnaire asks participants to rate their agreement with a series of statements using a six-point Likert scale, ranging from "never" (0) to "always" (5). Item responses are summed to generate a raw score ranging from 4 to 20, which is then converted to a standardized T-score using PROMIS scoring guidelines. Higher scores indicate greater depressive symptom severity.

    Time frame: From baseline (randomization) to 120 days after study drug initiation

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Data collected for this study will be shared only after the publication of findings addressing the study's specific aims. Data generated under this project will be managed in accordance with the policies of Weill Cornell Medicine (WCM) and the NIH, including the NIH Data Sharing Policy and Implementation Guidance. After publication of our main findings, data will be made available for secondary analyses. External researchers may request access to the data by submitting a written proposal outlining the hypotheses to be tested. All data will be de-identified to protect participant confidentiality.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: The data will be shared after we have published the primary results of this study. There is no end date to access the data from the research project.

Access criteria: Researchers granted access to the data will be required to use it solely for research purposes, ensuring that no individual participants are identifiable. They must also implement appropriate security measures, such as using password-protected servers and files, to safeguard the data. Upon completion of the analyses, the data must be returned or destroyed. Released datasets will be subject to stringent safeguards to ensure compliance with the Health Insurance Portability and Accountability Act (HIPAA). Additionally, a data-sharing agreement will be required, specifying that the data is used exclusively for research purposes and that no participants are identifiable. Any additional approvals required by participating institutions, including KPNC, will be obtained. A data management plan will also be necessary to ensure the continued security and confidentiality of the data, as well as to outline the process for returning or destroying the data once the analysis is complete.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Apr 2029, 38 months after the start.

Of 165 non-industry phase 4 interventional studies under Heart Failure, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 56. This study's planned 38 months is above that.

Counting every sponsor, half of 184 studies reached it within 31 months; a quarter within 21 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2025
First posted
Dec 23, 2025
StartActual
Feb 2, 2026
Primary completionEst.
Apr 2029
CompletionEst.
Apr 2029
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited, 2 added; 3 exclusion criteria edited, 2 removed
What changed in the criteria
Inclusion criteria
  • AddedEvidence of HF, defined by at least one of the following:
  • AddedBNP >100 pg/mL in the past 24 months
  • EditedKaiser PermanencePermanente Northern California Membership
Exclusion criteria
  • EditedHospitalization for a primary discharge diagnosis of atrial fibrillation or atrial flutter with a rapid ventricular response in the prior 12 months (i.e., not for an elective procedure such as a cardioversion or an ablation)
  • RemovedEvidence of recent decompensated HF
  • RemovedChange in loop diuretic pharmacy prescription in the past 30 days (i.e. pharmacy prescription data) (Note: This definition is based on documented prescription changes and does not include short-term dose adjustments that were verbally communicated to the patient by their provider.)
  • EditedDiagnosed dementia (i.e.., diagnostic codes)
  • EditedLoss of Kaiser PermanencePermanente Northern California Membership
Oct 16, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameThe Hierarchical Composite EndpointFrom baseline (day 0) to end of the follow-up phase (day 120) → From baseline (randomization) to 120 days after study drug initiation
Oct 16, 2026
Secondary outcomes
2 time frame changed
What changed in the outcomes
  • Time frameThe change from baseline in patient-reported physical health, as measured by the KCCQ-12Baseline, Day 120 → From baseline (randomization) to 120 days after study drug initiation
  • Time frameThe change in patient-reported mental health, as measured by the PROMIS Depression scaleBaseline, Day 120 → From baseline (randomization) to 120 days after study drug initiation
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Eligibility 1 inclusion criterion edited, 2 added; 3 exclusion criteria edited, 2 removed
    What changed in the criteria
    Inclusion criteria
    • AddedEvidence of HF, defined by at least one of the following:
    • AddedBNP >100 pg/mL in the past 24 months
    • EditedKaiser PermanencePermanente Northern California Membership
    Exclusion criteria
    • EditedHospitalization for a primary discharge diagnosis of atrial fibrillation or atrial flutter with a rapid ventricular response in the prior 12 months (i.e., not for an elective procedure such as a cardioversion or an ablation)
    • RemovedEvidence of recent decompensated HF
    • RemovedChange in loop diuretic pharmacy prescription in the past 30 days (i.e. pharmacy prescription data) (Note: This definition is based on documented prescription changes and does not include short-term dose adjustments that were verbally communicated to the patient by their provider.)
    • EditedDiagnosed dementia (i.e.., diagnostic codes)
    • EditedLoss of Kaiser PermanencePermanente Northern California Membership
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameThe Hierarchical Composite EndpointFrom baseline (day 0) to end of the follow-up phase (day 120) → From baseline (randomization) to 120 days after study drug initiation
    Secondary outcomes 2 time frame changed
    What changed in the outcomes
    • Time frameThe change from baseline in patient-reported physical health, as measured by the KCCQ-12Baseline, Day 120 → From baseline (randomization) to 120 days after study drug initiation
    • Time frameThe change in patient-reported mental health, as measured by the PROMIS Depression scaleBaseline, Day 120 → From baseline (randomization) to 120 days after study drug initiation
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07298993
Collaborators
National Institute on Aging (NIA), Kaiser Foundation Research Institute
Responsible party
Sponsor
First posted
Dec 23, 2025
Start date
Feb 2, 2026
Primary completion
Apr 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
Oct 16, 2026

Study contacts

Parag Goyal, MD, MSc
principal investigator · Weill Medical College of Cornell University
Andrew Ambrosy, MD, MPH
principal investigator · Kaiser Permanente

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beta blockers

Start the discussion